70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study
Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage Read More
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Publication: Heliyon 10 (2024) e39485 Authors: Daniele Generali, Andrea Read More
MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis
Publication: EMJ Oncol. 2024;12[1]:138-147. Authors: C. Jackisch, D. Pronin, Read More
Identification of Racial Disparities (ESMO 2024)
Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreNSABP B-42 Trial shows MammaPrint Low Risk is Predictive of EET – JCO Publication
Journal of Clinical Oncology, July 24, 2024 Authors: Rastogi, et al.
Read MoreGene-expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research, Vol 30, Issue 14, July 15 2024 Author: Bottosso et al.
Read MoreGene Expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research OF1–OF11, May 2024 Author: Bottosso et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreImproved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read More
